GSK Acquires Syndivia's Prostate Cancer ADC
GlaxoSmithKline (GSK) has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment.
Despite having its own ADC in development for prostate cancer, GSK is expanding its portfolio in this area, highlighting the industry's growing interest in the modality.
The gold standard of business intelligence.
GSK's move is expected to fuel the ongoing industry buzz for ADCs as a promising anti-tumor modality.
Author's summary: GSK buys Syndivia's prostate cancer ADC for £268m.